Guardant Health (GH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Guardant Health (GH) reported strong Q3 2025 results, with revenue reaching $265.2 million, a 38.5% year-over-year increase, significantly exceeding consensus estimates by 13.05%. The company also surpassed EPS expectations, reporting -$0.39 against an estimated -$0.48. Key operational metrics, including total oncology tests performed and revenue across its oncology, biopharma/data, and screening segments, all outperformed analyst projections, contributing to the stock's recent outperformance against the S&P 500.

Analysis

Guardant Health (GH) reported robust Q3 2025 results, with total revenue reaching $265.2 million, marking a substantial 38.5% year-over-year increase. This figure significantly surpassed the Zacks Consensus Estimate of $234.58 million by 13.05%, while EPS came in at -$0.39, an 18.75% positive surprise against the -$0.48 consensus.

The strong top-line performance was driven by broad-based operational strength, with total oncology tests performed reaching 74,000, exceeding the 66,824 estimate. Segmental revenue also outperformed, notably in Oncology ($184.4 million vs. $164.62 million estimated) and Screening ($24.11 million vs. $16.31 million estimated), indicating robust demand in core areas.

This strong earnings report has fueled positive market sentiment, with GH shares returning +11.4% over the past month, significantly outperforming the S&P 500's +3.8% change. Despite this momentum, the stock currently holds a Zacks Rank #3 (Hold), suggesting a potential near-term performance in line with the broader market.

Key Decisions for Investors

• Investors should monitor Guardant Health's continued operational execution, particularly in its high-growth segments like screening and oncology testing, to assess sustained momentum.
• Consider the implications of the strong Q3 beat and recent stock outperformance against the Zacks Rank #3 (Hold) rating, which suggests a more neutral near-term outlook.
• Evaluate the company's path to profitability, given the improving EPS figures, as a key long-term driver for valuation.